These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 34505112)
21. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659 [TBL] [Abstract][Full Text] [Related]
23. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders. Kaegi C; Wuest B; Crowley C; Boyman O Front Immunol; 2021; 12():788830. PubMed ID: 35185862 [TBL] [Abstract][Full Text] [Related]
25. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710 [TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Li H; Hu F; Zhang Y; Li K J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710 [TBL] [Abstract][Full Text] [Related]
33. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia. Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257 [TBL] [Abstract][Full Text] [Related]
34. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160 [TBL] [Abstract][Full Text] [Related]
35. Systemic treatments for eczema: a network meta-analysis. Sawangjit R; Dilokthornsakul P; Lloyd-Lavery A; Lai NM; Dellavalle R; Chaiyakunapruk N Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013206. PubMed ID: 32927498 [TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444 [TBL] [Abstract][Full Text] [Related]
37. Ocrelizumab: a new milestone in multiple sclerosis therapy. Mulero P; Midaglia L; Montalban X Ther Adv Neurol Disord; 2018; 11():1756286418773025. PubMed ID: 29774057 [TBL] [Abstract][Full Text] [Related]
38. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
39. Ocrelizumab for the treatment of multiple sclerosis. Bigaut K; De Seze J; Collongues N Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368 [TBL] [Abstract][Full Text] [Related]